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New Opportunities in Cancer Risk Evaluation
Using PCR-Based DNA Analysis for CYP2D6
by Jeffrey R. Idle' and Ann K. Daly'
Genetic polymorphisms ofdrug-metabolizing enzymes, principally CYP2D6 (debrisoquine 4-hydroxylase),
have long been considered influential on host responsiveness to environmental carcinogens. In several
independent studies, lung cancer cases are more frequently associated with the extensive metabolizer
phenotype of CYP2D6. However, assignment of phenotype has traditionally involved administration of
debrisoquine and analysis of drug and metabolite concentrations in patient urine and is thus potentially
confounded by concomitant drug therapy and the presence ofthe tumor itself. The development ofmolecular
genotyping methods offers unique opportunities to obviate these problems and to ascertain the relationship
between the presence ofindividual alleles and disease risk. Preliminary data are presented that indicate that
the CYP2D6 wild-type allele may be a predisposing factor in lung cancer.
Introduction
It is most appropriate that the findings in this report
should be presented atthe First International Conference
on Environmental Mutagenesis in Human Populations at
Risk in Cairo, for it was 15 years ago when an Egyptian
physician,AfafMahgoub,workingwith oneofus (J.R.I.) at
St. Mary's Hospital Medical School in London, first dis-
covered the genetic polymorphism in debrisoquine
4-hydroxylation (1). The intervening period haswitnessed
arenaissance inpharmacogenetics (2) and an explosion of
new drug substrates [see Caporaso and Shaw (3) for a
compendium] and potential roles for this polymorphic
enzyme, now referred to as CYP2D6 (4). Between 1 and
10% of various human populations have little or no
CYP2D6-mediated metabolic ability, andit was speculated
over a decade ago that this might lead to differential
susceptibility to lung cancer in cigarette smokers (5), even
though no tobacco carcinogen had been identified as a
CYP2D6 substrate. Onlyrecently has it emerged that the
tobacco-specific nitrosamine NNK [4-(methylnitro-
samino)-1-(3-pyridyl)-1-butanone] is metabolized to-muta-
genic products by CYP2D6 (6). Various case-control
studies have been carried out in lung cancer using the
phenotyping testdevelopedbyMahgoub etal. (1), thefirst
ofwhich (7,8) showed that the recessive poor metabolizer
(PM) phenotype was reduced from 9% in controls (n =
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234) to 1.4% in cases (n = 245). The lung cancer cases, all
ofwhom were northwestern European cigarette smokers
ofmorethan20pack-years, matchedforsmoking, age, and
sexwith the controls, were aggregated toward the fastest
metabolizing end of the spectrum. It was speculated (7)
that these might contain a higher-than-expected propor-
tion of homozygous dominant extensive metabolizers
(EM), the apparent at-risk genotype. However, the phe-
notyping test is unable to distinguish homozygous from
heterozygous EMsubjects. Manyothergroupshaveinves-
tigated the relationship between the EM/PM phenotype
andlungcancer,and, onbalance,thereexists amoderately
strong association between the EM phenotype and lung
cancer. [Readers are directed to an excellent review by
Caporaso et al. (9)]. Now the technology has become
available(10) toperformdirectgenotypinganalysisforthe
various alleles at the CYP2D6 gene locus that give rise to
the functional polymorphism observed after the admin-
istration ofdebrisoquine (1).
Collaborating laboratories in the United States and
Switzerland have principally solved much ofthe riddle of
the debrisoquine hydroxylation polymorphism [reviewed
in Gonzalez and Meyer (11)]. Using both restriction frag-
mentlength polymorphism (RFLP) andpolymerase chain
reaction(PCR)analyses, ithasbecomepossibletodetecta
number ofdiscrete mutations that cause the deficient PM
phenotype in 1-10% of populations. Figure 1 shows a
simplified schematic representation of the CYP2D locus,
which comprises one actively transcribed gene (CYP2D6)
and two highly homologous pseudogenes (CYP2D7P and
CYP2D8P). Insertions, deletions, and point mutations
have all been found, and 95% ofPMs can nowbe detected
unequivocally by these methods (10). In addition, and for
the firsttime, it is possible to assign correctlythe hetero-IDLE AND DALY
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metabolism of carrying either one (heterozygous EM) or
two (PM) mutant alleles [(10) Fig. 2]. PMs have metabolic
ratios [MR; urinary % dose and debrisoquine/% dose as
4-hydroxydebrisoquine (1)] greater than 10, homozygous
EMs have, in almost all cases, MRs <0.6, and the hetero-
zygotes are intermediate between the two with a modal
value at 1.0. There is therefore a gene-dose effect on
metabolism. For the first time this permits us to reevalu-
ate the original data ofAyesh et al. (7) by estimating the
proportion of cancer cases and controls who, from their
MR values, were likely to have been of the homozygous
dominant wild-type genotype (wt/wt). To accomplish this
maneuver, a graph of probability of being wt/wt versus
metabolic ratio was constructed and is shown in Figure 3.
In this paper we use this relationship to estimate the
number of cases and controls at each MR increment who
were likely to have been wt/wt homozygotes, the genotype
first proposed to be at highest risk of lung cancer in
smokers (7).
Estimated Genotype Distribution in
the Lung Cancer Cases and Controls
of Ayesh et al.
It has been our experience that subjects phenotyped by
gas chromatography at St. Mary's Hospital Medical
School in the early 1980s have the same metabolic ratio
values when rephenotyped in our laboratories today. We
feltjustified therefore inusingtherelationship in Figure 3
(derived from the Figure 2 data from the current study),
as a calibration curve to estimate retrospectively the
genotypes of the 1984 study population (7). This exercise
yields the two distributions depicted in Figure 4. The
cancer cases, as one would expect from the distribution in
Figure 2, have apreponderance ofwt/wt subjects, explain-
ingwhyAyesh et al. (7) observed the skewed distribution
FIGUJRE 1. Schematic representation of the CYP2D locus showing the
transcribed gene CYP2D6 and the two pseudogenes CYP2D7P and
CYP2D8P. Horizontal arrows represent the principal fragments after
Xbal digestion detected on Southern blotting with a full-length cDNA
probe (10).
zygous EM genotype in 98% ofcases (10), thus the oppor-
tunity exists to reevaluate the lung cancer association
using these methods. Although long-term studies are
underway in several laboratories, we report here the
rationale for such studies together-with areassessment of
the original debrisoquine hydroxylation data (7) in lung
cancer cases and controls.
Relationship between Metabolic
Phenotype and CYP2D6Genotype
By studying a random, healthy population with both
debrisoquine administration (phenotyping) and genomic
DNA analysis (genotyping), together with genotyping a
panel of 22 subjects previously phenotyped as PMs, we
have been able to visualize the effect on debrisoquine
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FIGIJRE 2. Relationship between CYP2D6 genotype and metabolic ratio
(see text). Filled bars, hatched bars, and stippled bars represent homo-
zygous wild-type/wild-type, heterozygous wild-type/mutant, and homo-
zygous mutant/mutant genotypes, respectively.
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FIGURE 3. Relationshipbetweenmetabolicratio (seetext)andtheproba-
bilityofbeingwild-type/wild-type genotype. Dataarederived essentially
from Figure 2.
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FIGURE 4. Depiction of the calculated wild-type/wild-type subjects at
each incremental metabolic ratio for both lung cancer cases (1) and
controls (U) from the metabolic data ofAyesh et al. (7).
of cases toward a lower metabolic ratio compared to
controls. The wt/wt genotype was estimated to occur in
56.0 and 26.7% of cases and controls, respectively, which
gives an approximate relative risk (12) of1.79forthewt/wt
genotype. In the earlier phenotypic analysis of these
patients (8), persons with an MRvalue <1.0were at4-fold
riskoflungcancer. In the analysis presented here, 35/234
(14.9%) and 127/245 (51.7%) of the controls and cases,
respectively, had both MR values <1.0 and the wt/wt
genotype. The relative risk ratio for such persons is 2.17,
somewhat less than the value determined byphenotyping
alone (vide supra). Atpresentwe are able to conclude that
wt/wt persons are at approximately twice the risk oflung
cancer than those who harbor one or two mutated alleles.
Discussion
Afterpublication ofthe original study showing an asso-
ciation between extensivemetabolism ofdebrisoquine and
lungcancer(7),various groups claimedthattheeffectmay
not have been one ofdisease causation, but a result ofthe
disease itself. Perhaps concomitant drug therapy, ectopic
hormones, alterations in renal function, or immunological
changes in the cancer group resulted in our findings.
Although none of these confounders could be substanti-
atedfromthevastamountofclinical dataonthesepatients
available for epidemiological analysis, it nevertheless
remained as a setoftheoretical possibilities, nothelped by
thefact that, until 1991 (6), notobacco carcinogen couldbe
identified as a substrate of CYP2D6. The availability of
recombinant DNA technology has not only permitted
workers to screen promutagens and procarcinogens in
human cells with enhanced cDNA-directed expression of
CYP2D6 (6), but also has allowed clarification of the
relationship between discrete genotype and debrisoquine
metabolism invivo. Ithas indeed been confirmed thatthe
fastest metabolizers are almost invariably of the wt/wt
genotype. Onlythe ongoing and asyetunreported studies
will confirm ordenythe relationship between the wt allele
and cancer risk. In the meantime, however, we have
reported here an estimation ofthe likely number ofwt/wt
subjects in the original case-control study (7). These
deductions lead to the expectation offinding no more than
a 2-fold difference in relative risk forthis wt/wt genotype,
somewhat less than the metabolic studies would indicate.
It is probable, indeed highly likely, that several meta-
bolic polymorphisms influence the process of chemical
carcinogenesis in at-riskpopulations (13). Recognized can-
didates, in addition to CYP2D6, are CYPlAl (formerly
AHH) andtheglutathione S-transferase GST-,u (13). How-
ever, data are beginning to emerge concerning polymor-
phisms ofothercandidategenes,particularlyCYP1A2 and
CYP2E1, which also code for cytochrome P450 isozymes.
Future prospects of learning considerably more about
cancer risk by the study of a battery of such genes are
extremely good. It is hard to envisage how functional
genetic polymorphisms ofthese enzymes, which both acti-
vate and detoxicate environmental mutagens, would notin
major part determine genotoxicity in the individual and
thus cancerrisk. Onlybyharnessingthe skills ofboth the
clinical epidemiologist and thelaboratoryscientistwillthe
jigsaw finally take shape.
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